Pfizer’s breast cancer drug Ibrance, or palbociclib, is too expensive to justify its use on Britain’s state-run health service, the country’s healthcare cost-effectiveness watchdog said on Friday. The logo of Dow Jones Industrial Average stock market index listed company Pfizer is pictured here in La Jolla, California April 21, 2016.